AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.
Also called NCT01118520
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 224 participants
- Registry
-
NCT01118520 -
2010-020226-17
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01118520. Randomized; triple masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2015-04 (actual). Results posted on 2021-01-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
- Acronym
- AARDVARK
- Condition
- Abdominal Aortic Aneurysm
- Intervention (Drug)
- perindopril arginine
- Intervention (Drug)
- amlodipine 5mgs
- Intervention (Drug)
- placebo
- Lead sponsor
- Imperial College London
- Collaborator
- National Institute for Health Research, United Kingdom
Record details
- Record id
cardio:ct-nct01118520- Content hash
ecf11ad52e8751dbe314dca65bf85b00d9ae315b2d727c62a13c1e233ae440a7